Whipplewood Advisors LLC Acquires 4,132 Shares of CRISPR Therapeutics AG $CRSP

Whipplewood Advisors LLC increased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 82,640.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,137 shares of the company’s stock after purchasing an additional 4,132 shares during the quarter. Whipplewood Advisors LLC’s holdings in CRISPR Therapeutics were worth $201,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. SVB Wealth LLC bought a new stake in shares of CRISPR Therapeutics in the first quarter worth $25,000. Costello Asset Management INC acquired a new position in CRISPR Therapeutics in the first quarter valued at $27,000. Quantbot Technologies LP lifted its holdings in CRISPR Therapeutics by 272.4% in the first quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after buying an additional 978 shares during the period. IFP Advisors Inc lifted its holdings in CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after buying an additional 181 shares during the period. Finally, GF Fund Management CO. LTD. lifted its holdings in CRISPR Therapeutics by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after buying an additional 394 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Up 0.6%

Shares of NASDAQ CRSP opened at $67.61 on Monday. The firm’s 50-day moving average price is $61.62 and its 200-day moving average price is $51.52. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The firm has a market capitalization of $6.15 billion, a P/E ratio of -12.45 and a beta of 1.84.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. During the same quarter in the prior year, the business earned ($1.49) earnings per share. The business’s quarterly revenue was up 72.5% compared to the same quarter last year. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on CRSP. Chardan Capital restated a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Bank of America boosted their target price on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a report on Friday, October 17th. JPMorgan Chase & Co. began coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 target price on the stock. Finally, Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a report on Monday, October 13th. Ten research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $72.59.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,213 shares of company stock valued at $3,810,458. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.